AA82231

160003-66-7 | 4-Iodo-3-nitrobenzamide

Name: Name:4-Iodo-3-nitrobenzamide
Brand: A2BChem
SKU: AA82231
Availability: InStock
Rating: 95 (1 reviews)

Packsize	Purity	Availability	Price	Discounted Price	Quantity
1mg	98%	in stock	$11.00	$8.00	- +
5mg	98%	in stock	$13.00	$9.00	- +
10mg	98%	in stock	$16.00	$11.00	- +
25mg	98%	in stock	$19.00	$13.00	- +
100mg	98%	in stock	$28.00	$20.00	- +
250mg	98%	in stock	$34.00	$24.00	- +
1g	98%	in stock	$41.00	$29.00	- +
5g	98%	in stock	$71.00	$50.00	- +
25g	98%	in stock	$248.00	$174.00	- +

*All products are for research use only and not intended for human or animal use.

*All prices are in USD.

Request Bulk Quote

Download SDS

Description

Catalog Number:	AA82231
Chemical Name:	4-Iodo-3-nitrobenzamide
CAS Number:	160003-66-7
Molecular Formula:	C7H5IN2O3
Molecular Weight:	292.0307
MDL Number:	MFCD11110639
SMILES:	[O-][N+](=O)c1cc(ccc1I)C(=O)N

Computed Properties

Complexity:	228
Covalently-Bonded Unit Count:	1
Heavy Atom Count:	13

Hydrogen Bond Acceptor Count:	3
Hydrogen Bond Donor Count:	1
Rotatable Bond Count:	1
XLogP3:	1.3

Literature

Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle.
Cell metabolism 20140603
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters 20130801
Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study.
Gynecologic oncology 20120901
Neoadjuvant treatments for triple-negative breast cancer (TNBC).
Annals of oncology : official journal of the European Society for Medical Oncology 20120801
Current and emerging targeted therapies for metastatic breast cancer.
Cancer 20120615
Dissecting the heterogeneity of triple-negative breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120520
Re: potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer.
Journal of the National Cancer Institute 20120502
Nickel-catalysed aromatic Finkelstein reaction of aryl and heteroaryl bromides.
Chemical communications (Cambridge, England) 20120425
[PARP inhibitors and breast cancer: update and perspectives].
Bulletin du cancer 20120401
Drug candidates derailed in case of mistaken identity.
Nature 20120328
Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.
Clinical cancer research : an official journal of the American Association for Cancer Research 20120315
Present status and problems on molecular targeted therapy of cancer.
Cancer research and treatment : official journal of Korean Cancer Association 20120301
Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.
Clinical cancer research : an official journal of the American Association for Cancer Research 20120115
Basal breast cancer: a complex and deadly molecular subtype.
Current molecular medicine 20120101
Ovarian cancer: opportunity for targeted therapy.
Journal of oncology 20120101
BRCAness profile of sporadic ovarian cancer predicts disease recurrence.
PloS one 20120101
Molecular basis of triple negative breast cancer and implications for therapy.
International journal of breast cancer 20120101
Current Status of Poly(ADP-ribose) Polymerase Inhibitors as Novel Therapeutic Agents for Triple-Negative Breast Cancer.
International journal of breast cancer 20120101
Major clinical research advances in gynecologic cancer in 2011.
Journal of gynecologic oncology 20120101
Advances in using PARP inhibitors to treat cancer.
BMC medicine 20120101
Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.
Journal of oncology 20120101
Metastasis of neuroendocrine tumors are characterized by increased cell proliferation and reduced expression of the ATM gene.
PloS one 20120101
Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone.
Journal of oncology 20120101
The first European interdisciplinary ewing sarcoma research summit.
Frontiers in oncology 20120101
Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer.
Journal of the National Cancer Institute 20111207
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.
Therapeutic advances in medical oncology 20111101
Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition.
Cancer science 20111001
PARP inhibitors--current status and the walk towards early breast cancer.
Breast (Edinburgh, Scotland) 20111001
DNA-damaging therapies emerging as possible triple-negative breast cancer therapies.
Oncology (Williston Park, N.Y.) 20111001
PARP inhibitors: its role in treatment of cancer.
Chinese journal of cancer 20110701
Novel agents and future directions for refractory breast cancer.
Seminars in oncology 20110601
Iniparib in metastatic triple-negative breast cancer.
The New England journal of medicine 20110505
Few positives for triple-negative breast cancer.
Journal of the National Cancer Institute 20110406
Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.
Anticancer research 20110401
Triple negative breast cancer: unmet medical needs.
Breast cancer research and treatment 20110201
Iniparib plus chemotherapy in metastatic triple-negative breast cancer.
The New England journal of medicine 20110120
PARP and cancer--if it's broke, don't fix it.
The New England journal of medicine 20110120
PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy.
Acta clinica Belgica 20110101
Promising molecular targeted therapies in breast cancer.
Indian journal of pharmacology 20110101
Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.
Cancer management and research 20110101
Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells.
BMC pharmacology 20110101
Drug therapy for hereditary cancers.
Hereditary cancer in clinical practice 20110101
Management options in triple-negative breast cancer.
Breast cancer : basic and clinical research 20110101
Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?
Breast cancer research : BCR 20110101
Tips and tricks in triple-negative breast cancer: how to manage patients in real-life practice?
Ecancermedicalscience 20110101
Triple-negative breast cancer: adjuvant therapeutic options.
Chemotherapy research and practice 20110101
[PARP inhibitors to treat triple negative breast cancer].
Gan to kagaku ryoho. Cancer & chemotherapy 20101201
Iniparib, a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer.
IDrugs : the investigational drugs journal 20100901
Small-molecule PARP modulators--current status and future therapeutic potential.
Current opinion in drug discovery & development 20100901
Beyond PARP inhibitors: agents in pipelines target DNA repair mechanisms.
Journal of the National Cancer Institute 20100804
Treatment options for patients with triple-negative breast cancer.
Journal of hematology & oncology 20100101
Directed therapy of subtypes of triple-negative breast cancer.
The oncologist 20100101
Enzymatic mechanism of the tumoricidal action of 4-iodo-3-nitrobenzamide.
Molecular medicine reports 20090101
Anti-cancer action of 4-iodo-3-nitrobenzamide in combination with buthionine sulfoximine: inactivation of poly(ADP-ribose) polymerase and tumor glycolysis and the appearance of a poly(ADP-ribose) polymerase protease.
Biochemical pharmacology 20020201
Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture.
Biochemical pharmacology 19950825